Advertisement
UK markets closed

  • FTSE 100

    8,237.72
    -34.74 (-0.42%)
     

  • FTSE 250

    20,442.35
    -56.37 (-0.27%)
     

  • AIM

    772.57
    +0.19 (+0.02%)
     

  • GBP/EUR

    1.1822
    +0.0000 (+0.00%)
     

  • GBP/USD

    1.2650
    -0.0010 (-0.08%)
     

  • Bitcoin GBP

    50,920.25
    +144.53 (+0.28%)
     

  • CMC Crypto 200

    1,350.97
    -9.35 (-0.69%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • DOW

    39,150.33
    +15.57 (+0.04%)
     

  • CRUDE OIL

    80.59
    -0.70 (-0.86%)
     

  • GOLD FUTURES

    2,334.70
    -34.30 (-1.45%)
     

  • NIKKEI 225

    38,596.47
    -36.55 (-0.09%)
     

  • HANG SENG

    18,028.52
    -306.80 (-1.67%)
     

  • DAX

    18,163.52
    -90.66 (-0.50%)
     

  • CAC 40

    7,628.57
    -42.77 (-0.56%)
     
Property:

Homes with impressive sports facilities

Properties with tennis and basketball courts to pools and even a football pitch at the doorstep

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

PR Newswire
·1-min read

CAMBRIDGE, Mass., May 29, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:30 p.m. ET in NYC.

Nuvalent, Inc. (PRNewsfoto/Nuvalent, Inc.)
Nuvalent, Inc. (PRNewsfoto/Nuvalent, Inc.)

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-2024-jefferies-global-healthcare-conference-302157212.html

SOURCE Nuvalent, Inc.